
Consortium invests $30m in series-B round for Eyevensys
Boehringer Ingelheim Venture Fund has led a $30m series-B round for France-based Eyevensys, a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases.
Latest News
Secondaries GPs expect record 2022 – Investec
Fifth Secondaries Market Report also reveals that 97% of secondaries investors are participating in GP-leds
Eurazeo in exclusivity for Sevetys acquisition
French sponsor beats Ardian and Antin in race for a majority stake in French veterinary chain
VC Profile: Octopus backs pre-seed ecocystem with fresh fund
Fund is headed by Kirsten Connell and Maria Rotilu and has extended its hard cap to GBP 15m following a first close
Bowmark backs Cornwall Insight buyout
BGF exits energy markets consultancy following minority stake investment in 2017
Back to Top